{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023129","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.134235+00:00","generated_at":"2026-05-22T07:24:59.021468+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook","bullets":["Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).","Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.","Adjusted EBITDA of $4.9M, up from $0.7M in prior year.","Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.","Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023129","json":"https://secwatch.observer/filing/0001628280-25-023129.json","markdown":"https://secwatch.observer/filing/0001628280-25-023129.md","text":"https://secwatch.observer/filing/0001628280-25-023129.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/0001628280-25-023129-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/cdxc-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:24:59.021468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}